血清定量HBsAg和HBV DNA预测HBeAg阳性慢性HBV感染显著肝炎活动的性能比较

摘要/Abstract

摘要： 目的对比评价血清HBsAg和HBV DNA预测HBeAg阳性慢性HBV感染显著肝炎活动的性能。方法 505例HBeAg阳性患者入选本研究。HBsAg、HBeAg采用Architect I2000免疫分析仪检测,HBV DNA采用LightCycler 480 qPCR仪检测;血清ALT采用Architect C16000生化分析仪检测。肝脏病理学分级和分期参照Scheuer标准。显著肝炎活动分三个层级,依次定义为“ALT≥20 IU/L或(分级>G1或分期>S1)”、“ALT≥30 IU/L或(分级>G1或分期>S1)”、“ALT≥40 IU/L或(分级>G1或分期>S1)”。结果根据ALT与HBsAg、HBeAg和HBV DNA的LOESS回归分析,279例患者被界定为疑似HBV高复制人群。总体人群,HBsAg和HBV DNA预测三个层级显著肝炎活动的ROC曲线下面积(AUC)依次为0.737和0.532、0.737和0.548、0.686和0.545,疑似HBV高复制人群,HBsAg和HBV DNA预测三个层级显著肝炎活动的AUC依次为0.866和0.544、0.837和0.540、0.787和0.564。无论总体或疑似HBV高复制人群,HBsAg和HBV DNA预测三个层级显著肝炎活动的AUC分别均显著大于和均接近对角参考线下面积(P均<0.002和P均>0.150),HBsAg预测三个层级显著肝炎活动的AUC均显著大于HBV DNA(P<0.001)。以HBsAg≤4.699 log10 IU/mL为标准,其预测总体人群ALT≥20 IU/L、≥40 IU/L显著肝炎活动的灵敏度和特异度分别为86.50%和56.25%、89.52%和43.94%,预测疑似HBV高复制人群ALT≥20 IU/L、≥40 IU/L显著肝炎活动的灵敏度和特异度分别为75.37%和81.82%、80.51%和67.44%。结论 HBsAg对HBeAg阳性显著肝炎活动有良好预测意义,而HBV DNA没有预测价值。

关键词: 乙型肝炎表面抗原, 定量, 乙型肝炎病毒感染, 慢性, 自然史

Abstract: Objective To comparatively evaluate the performance of serum HBsAg and HBV DNA in predicting significant hepatitis activity in HBeAg-positive patients with chronic HBV infection. Methods 505 HBeAg-positive patients were enrolled. HBsAg and HBeAg were measured in an Abbott Architect I2000 automatic immunoassay system, HBV DNA was measured in a Roche LightCycler 480 qPCR system, and serum ALT was measured in an Abbott Architect C16000 automatic biochemical analysis system. Diagnoses of Liver pathological grade and stage referred to the Scheuer standard. Significant hepatitis activity was divided into three levels, which were successively defined as “ALT≥20 IU/L or (pathological grade>G1 or stage>S1)”, “ALT≥30 IU/L or (pathological grade>G1 or stage>S1)”, and “ALT≥40 IU/L or (pathological grade>G1 or stage>S1)”. Results According to LOESS regression analyses of ALT with HBsAg, HBeAg and HBV DNA, 279 patients were classified as possible high HBV replication population. In the total number of infected, the areas under ROC curve (AUCs) of HBsAg and HBV DNA for predicting the three levels of significant hepatitis activity were successively 0.737 and 0.532, 0.737 and 0.548, and 0.686 and 0.545; in possible high HBV replication population, the AUCs of HBsAg and HBV DNA for predicting the three levels of significant hepatitis activity were successively 0.866 and 0.544, 0.837 and 0.540, and 0.787 and 0.564. In both overall and possible high HBV replication population, the AUCs of HBsAg and HBV DNA for predicting the three levels of significant hepatitis activity were all significantly greater than and all close to the area under diagonal reference line (all P<0.002 and all P>0.150); and the AUCs of HBsAg for predicting the three levels of significant hepatitis activity were all significantly greater than those of HBV DNA (P<0.001). With standard of HBsAg≤4.699 log10 IU/mL, the sensitivity and specificity of HBsAg for predicting significant hepatitis activity with ALT≥20 IU/L, ALT≥40 IU/L of overall population were 86.50% and 56.25%, 89.52% and 43.94%, respectively; and of possible high HBV replication population were 75.37% and 81.82%, 80.51% and 67.44%, respectively.Conclusion HBsAg has good performance and HBV DNA has no value in predicting significant hepatitis activity in patients with HBeAg-positive chronic HBV infection.

Key words: Hepatitis B surface antigen, Quantitative, Hepatitis B virus infection, Chronic, Natural history

陆伟, 张占卿, 阎俪, 黄丹, 林维佳, 周新兰, 丁荣蓉, 王雁冰, 李秀芬. 血清定量HBsAg和HBV DNA预测HBeAg阳性慢性HBV感染显著肝炎活动的性能比较[J]. 肝脏, 2023, 28(1): 86-94.

LU Wei, ZHANG Zhan-qing, YAN Li, HUANG dan, LIN Wei-jia, ZHOU Xin-lan, DING Rong-rong, WANG Yan-bing, LI Xiu-fen. Performance comparison of quantitative serum HBsAg and HBV DNA in predicting significant hepatitis activity in patients with HBeAg-positive chronic HBV infection[J]. Chinese Hepatolgy, 2023, 28(1): 86-94.

参考文献

[1] Sarin SK, Kumar M, Lau GK, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int, 2016, 10(1): 1-98.
[2] European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol, 2017, 67(2): 370-398.
[3] Terrault NA, Lok ASF, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology, 2018, 67(4): 1560-1599.
[4] 中华医学会感染病学分会, 中华医学会肝病学分会. 慢性乙型肝炎防治指南(2019年版). 临床肝胆病杂志, 2019, 35(12): 2648- 2669.
[5] Normal limits of serum alanine aminotransferase in healthy population: A systematic review. Middle East J Dig Dis, 2020, 12(3): 194-205.
[6] Kumar M, Sarin SK, Hissar S, et al. Virological and histological features of chronic hepatitis B virus infected asymptomatic patients with persistently normal ALT. Gastroenterology, 2008, 134(5): 1376-1384.
[7] Gui HL, Wang H, Yang YH, et al. Significant histopathology in Chinese chronic hepatitis B patients with persistently high-normal alanine aminotransferase. J Viral Hepat, 2010, 17 (Suppl. 1), 44-50.
[8] Liao B, Wang Z, Lin S, et al. Significant fibrosis is not rare in Chinese chronic hepatitis B patients with persistent normal ALT. PLoS ONE, 2013, 8(10): e78672.
[9] Xing YF, Zhou DQ, He JS, et al. Clinical and histopathological features of chronic hepatitis B virus infected patients with high HBV-DNA viral load and normal alanine aminotransferase level: A multicentre-based study in China. PLoS ONE, 2018, 13(9): e0203220.
[10] Kumar M, Sarin SK. Hepatitis B virus immunotolerant patients: need to differentiate patients with or without liver disease. Gastroenterology, 2009, 137(2): 742-743.
[11] Zhang ZQ, Shi BS, Lu W, et al. Quantitative HBcrAg and HBcAb versus HBsAg and HBV DNA in predicting liver fibrosis levels of chronic hepatitis B patients. Gastroenterol Hepatol, 2020, 43(9): 526-536.
[12] Cornberg M, Wong VWS, Locarnini S, et al. The role of quantitative hepatitis B surface antigen revisited. J Hepatol, 2017, 66(2): 398-411.
[13] Pollicino T, Caminiti G. HBV-integration studies in the clinic: Role in the natural history of infection. Viruses, 2021, 13(3): 368.
[14] Mak LY, Seto WK, Fung J, et al. Use of HBsAg quantification in the natural history and treatment of chronic hepatitis B. Hepatol Int, 2020, 14(1): 35-46.
[15] Nguyen T, Thompson AJ, Bowden S, et al. Hepatitis B surface antigen levels during the natural history of chronic hepatitis B: a perspective on Asia. J Hepatol 2010, 52(4): 508-513.
[16] Jaroszewicz J, Calle Serrano B, Wursthorn K, et al. Hepatitis B surface antigen (HBsAg) levels in the natural history of hepatitis B virus (HBV)-infection: a European perspective. J Hepatol, 2010, 52(4): 514-522.
[17] Zhang ZQ, Zhang XN, Lu W, et al. Distinct patterns of serum hepatitis B core-related antigen during the natural history of chronic hepatitis B. BMC Gastroenterol, 2017, 17(1): 140.
[18] Zhang ZQ, Wang YB, Lu W, et al. Performance of hepatitis B core-related antigen versus hepatitis B surface antigen and hepatitis B virus DNA in predicting HBeAg-positive and HBeAg-negative chronic hepatitis. Ann Lab Med, 2019, 39(1): 67-75.
[19] Brunt EM. Grading and staging the histopathological lesions of chronic hepatitis: the Knodell histology activity index and beyond. Hepatology, 2000, 31(1): 241-246.
[20] Milich DR. The concept of immune tolerance in chronic hepatitis B virus infection is alive and well. Gastroenterology, 2016, 151(5): 801-804.
[21] Han Q, Lan P, Zhang J, et al. Reversal of hepatitis B virus-induced systemic immunetolerance by intrinsic innate immune stimulation. J Gastroenterol Hepatol, 2013, 28 (Suppl. 1): 132-137.
[22] Guidotti LG, Isogawa M, Chisari FV. Host-virus interactions in hepatitis B virus infection. Curr Opin Immunol, 2015, 36: 61-66.
[23] Peeridogaheh H, Meshkat Z, Habibzadeh S, et al. Current concepts on immunopathogenesis of hepatitis B virus infection, Virus Research, 2018, 245: 29-43.
[24] Velazquez VM, Grakoui A. Immune quiescence and hepatitis B virus: Tolerance has its limits. Gastroenterology, 2012, 143(3): 529-532.
[25] Li TY, Yang Y, Zhou G, et al. Immune suppression in chronic hepatitis B infection associated liver disease: A review. World J Gastroenterol, 2019, 25(27): 3527-3537.
[26] Kramvis A, Kostaki EG, Hatzakis A, et al. Immunomodulatory function of HBeAg related to short-sighted evolution, transmissibility, and clinical manifestation of hepatitis B virus. Front Microbiol, 2018, 9: 2521.
[27] Mannan R, Misra V, Misra SP, et al. A comparative evaluation of scoring systems for assessing necro-inflammatory activity and fibrosis in liver biopsies of patients with chronic viral hepatitis. J Clin Diagn Res, 2014, 8(8): FC08-12.